North Carolina lawmakers could be backing medical cannabis soon, and it could herald the beginning of the end for prohibition in the state.
Articles
Bill To Legalize Safe Consumption Sites For Drugs Heads To Rhode Island Governor’s Desk
The Rhode Island legislature on Thursday sent a bill to the governor’s desk that would establish a safe consumption site pilot program where people could test and use currently illicit drugs in a medically supervised environment.
Psychedelic Stocks: An Investing Hedge For A Crazy World
As investors become increasingly concerned about hedging their portfolios, there are few safe alternatives. Psychedelic stocks are a sane choice for a crazy world.
Adult-Use Cannabis Possession Now Legal in Connecticut and Virginia
Portions of the legislature-approved legalization laws in Connecticut and Virginia take effect today including possession and use for adults 21-and-older in both states.
Maxim Group Initiates Coverage of Mind Cure Health
Analysts Jason McCarthy and Michael Okunewitch of Maxim Group have initiated coverage of Mind Cure Health.
Harvard University Launches First-Of-Its-Kind Psychedelics Policy Center
Harvard Law School on Wednesday announced the launch of a first-of-its-kind psychedelics policy center that it hopes will inform legislation and help clinicians navigate this burgeoning medical space as reform continues to advance.
The Mental Health Pandemic Soars Into Focus, Psychedelics In The Spotlight
As the Mental Health Pandemic spirals out of control, we see a positive sign: the mainstream media has finally noticed it.
Clarence Thomas says federal laws against marijuana may no longer be necessary
Clarence Thomas, one of the Supreme Court's most conservative justices, said Monday that because of the hodgepodge of federal policies on marijuana, federal laws against its use or cultivation may no longer make sense.
Psyched Wellness Commences Next Pre-Clinical Study on AME-1
Psyched Wellness announces its latest pre-clinical study on AME-1.
Cybin Inc. Releases Annual Financials and Provides Business Highlights
Cybin Inc releases its full-year financial results for the fiscal year ended March 31, 2021 and provides business highlights.
Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement
In pre-clinical testing, multiple proprietary molecules "showed consistent positive results when compared to the parent molecule".
MindMed Included in FTSE Russell 3000® Index
MindMed officially announces its inclusion in the FTSE Russell 3000.
COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depression
Compass Pathways completes the world's largest psilocybin-based clinical trial as the 216th patient in its trial completed their treatment.
Use of mescaline may facilitate unintended improvements in several psychiatric conditions, study suggests
The use of mescaline, a psychedelic substance derived from the peyote cactus, appears to be associated with improvements in depression and anxiety, according to a new preliminary study published in the journal ACS Pharmacology & Translational Science.
Psychedelic Medicine: Will The High Always Be Part Of The Therapy?
Psychedelic Stock Watch explains why astute investors will put their dollars into both "experiential" and non-psychoactive psychedelic drug R&D.